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 Abstract  
 
Objective: The objective of this selective EBM review is to determine whether or not treatment 
with topical glyceryl trinitrate is effective in reducing elbow pain in patients with lateral 
epicondylitis.  
 
Study Design: Review of two English language randomized controlled trials and one primary 
study published 2003, 2009, 2011.  
 
Data Sources: Two double blind randomized controlled and one prospective comparison study 
comparing the effectiveness of gylceryl trinitrate to placebo in the treatment of pain related to 
lateral epicondylitis, found using PubMed, EBSCOhost, and CINAHL Plus.   
 
Outcome(s) Measured: The outcome studied was patient self-rated elbow pain at rest, pain with 
activity, pain at night, and local epicondylar and tendon tenderness, measured with Maudsley’s 
test (newtons) with dynamometer and wrist extension mean peak force, ORI-TESTS. 
 
Results: Paoloni et al (2003) showed pain and tenderness in 81% (35 of 43) patients in the GTN 
group were asymptomatic with activities of daily living, compared to 60% (26 of 43) in the 
placebo group. (p=0.005). The 2009 trial by Paoloni et al  was inconclusive due to 
discontinuation at 8 weeks due to insignificant findings. The prospective study by McCallum et 
al in 2011 was inconclusive, showing no difference between the GTN group and placebo group 
at 5 years post treatment.  
 
Conclusions:  
 
Key Words: Glyceryl trinitrate, lateral epicondlyitis 
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INTRODUCTION 
 
 Lateral epicondylitis, more commonly known as tennis elbow, is a chronic, inflammatory 
disorder of the extensor carpi radialis muscle attachment to the lateral prominence of the 
humerus, the epidondyle. It is due to overuse or repetitive movement of the forearm, such as the 
motion used when playing tennis, or when lifting heavy loads with the forearm pronated, or with 
grasping. It is characterized by pain and tenderness to palpation over the epicondyle. The muscle 
attachment over the epicondyle degenerates, causing the pain. It is often described clinically as a 
dull aching pain, which interferes with activities of daily life due to inability to fully use the 
affected arm. It commonly occurs in patients 30 – 50 years of age.1  
 To physician assistants who practice in general medicine and in musculoskeletal 
specialties, this is very common injury seen. It is seen between 1-3% of adults (3.2-9.6 million)1, 
and leads to many visits and decreased quality of life for patients. The economic burden on the 
health care system and on the patients was not estimated in any academic sources. However, 
with an average healing time of 18-24 months, it can be predicted that there are many hours lost 
from work. 
 Lateral Epicondylitis is a well-known and studied pathology. The mechanism of injury, 
as discussed above, is repeated stress to the tendon overlying the epicondyle, leading to 
degeneration and pain for the patient. Symptoms include morning stiffness, point tenderness, and 
pain with movement and gripping. It is a chronic condition, meaning that the symptoms last for 
greater than three months.1 It decreases quality of life for patients, who have pain with 
movement of the affected elbow for many months.  What is unknown about this condition is the 
most effective treatment, as there is no agreed upon treatment. There are many options, with 
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physical therapy being the most prominent. Also unknown, and relevant to this review, is the 
exact mechanism of action of glyceryl trinitrate.2   
 Most patients are indeed referred to PT, as this has yielded beneficial results, and is the 
mainstay treatment. However, many patients continue to complain about the chronic pain, and 
look for other options, if only for relief. These include NSAIDs, braces, corticosteroid injection, 
eletro-stimulation, surgery, and RICE (rest, ice, compression, elevation.)  
 The method proposed and studied by this particular review is treatment with topical 
glyceryl trinitrate (GTN) patches. This transdermal patch is used in conjunction with physical 
therapy, in hopes of increased nitrous oxide and blood flow to the area, allowing healing of the 
degenerated tendon. These patches have been shown effective in other tendonopathies. This 
treatment method is being study due to its non-invasiveness for a very common medical 
problem.2  
OBJECTIVE 
 The objective of this systematic review is to determine whether or not treatment with 
glyceryl trinitrate is effective in reducing pain in patients with lateral epicondylitis.  
METHODS 
 Criteria: In order to answer the above question, this review focuses on a population over 
the age 18, with a diagnosis of lateral epicondylitis. The interventions that were considered 
include treatment with GTN transdermal patch verses a placebo. The outcomes measured 
included patient rated pain at rest, with activity, and at night. The studies that are included are 
two RCT’s and one primary study, all of which met above parameters.2,3,4  
 Data Sources: The sources used for this review came from a search of databases looking 
at English language articles with the key words “lateral epicondylitis” and “glyceryl 
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trinitrate.”All articles were published in peer-reviewed articles, and were selected based on 
relevancy to the question asked, and if they included patient oriented outcomes that matter 
(POEMS). The search was done via PCOM library access to PubMed, EBSCOhost, and 
CINAHL Plus. Inclusion criteria for studies included randomization, double blind, and placebo 
control. A trial was excluded if it was published greater than 15 years in the past, patients who 
had an acute injury, or if a patient was under 18 years of age. Statistics used in these three trials 
were Relative Risk Reductions (RRR), Absolute Risk Reduction (ARR) Numbers needed to treat 
(NNT) and P-values.  
Study Type #Pts Age 
(years) 
Inclusion 
criteria 
Exclusion 
criteria 
W/D Interventions 
Paoloni 
(2003)4 
Double 
blind 
RCT 
86 >18 Patient over 
the age of 18 
who had 
diagnosis of 
chronic 
lateral 
epicondylitis 
Tendonosis 
< 3 month, 
pregnancy, 
Sx or 
dislocation, 
distal 
neuro 
signs, or 
steroid 
injection in 
last 3 mo 
8 ¼ of 
5mg/24hour 
Nitro-dur 
patch 
Murrell 
(2009)5 
Double 
Blind 
RCT 
154 18-70 Adults 18-70 
with dx of 
lateral 
epicondylitis, 
who scored > 
4 on visual 
1-10 pain 
scale 
BMI >38, 
regular 
oral/topical 
analgesia, 
steroid 
injection in 
last 3 mo, 
work comp 
cases, 
pregnancy, 
previous 
18 Orthoderm 
0.72mh/24hr 
Othroderm 
1.44mg/24hr 
Orthoderm 
3.6mg/24hr 
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OUTCOMES MEASURED  
 All outcomes measure in these three studies reviewed are POEMs. The major outcomes 
studied included patient rated elbow pain at rest, pain with activity, at night, and local 
epicondylar/tendon tenderness. The patients, using questionnaires, rated these categories.  Data 
was collected from the surveys and further analyzed. The major measurement used in all three 
studies was ORI-TETS, or the Orthopedic Research Institute Tennis Elbow Testing System.  
This test is designed to objectively measure force generated with a simulated chair pickup test.5 
Results were analyzed by statistical software (Sigmastat 2.0) by way of the Mann-Whitney rank 
sum test to compare the differences within groups. Significant findings were defined with P 
values of 0.05 or less. Patients rated safety and tolerability, with headaches and a dermatitis rash 
being a major side effect. EDIT  
RESULTS  
 All of the studies reviewed had patients who were previously diagnosed with lateral 
GTN use, 
cardiac dz, 
upper limb 
injury hx 
Paoloni 
et al 
(2009)2 
Primary 58 >18 Patient over 
the age of 18 
who had 
diagnosis of 
chronic 
lateral 
epicondylitis 
Tendonosis 
< 3 month, 
pregnancy, 
Sx or 
dislocation, 
distal 
neuro 
signs, or 
steroid 
injection in 
last 3 mo 
Follow 
up of 
RCT 
that 
had 12 
W/D 
¼ of 
5mg/24hour 
Nitro-dur 
patch 
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epicondylitis, and had agreed to follow up for the allotted time. Table One shows the 
demographics for the patients included in all three studies. The data was presented in 
dichotomous form for the two RCTs studied (Paoloni, Appleyard, Nelson, Murrel 2003; Paoloni 
Murrell, Burch, Ang 2009), and in continuous form that was converted to dichotomous in the 
primary study (McCallum, Paoloni, Murrell 2011).  
 In the RCT by Paoloni et al. (2003, Am Journal of Sports Medicine), 86 patients were 
selected for the trial, split evenly into 43 GTN and 43 placebo patients. In the GTN group, 5 
dropped out due to side effects (headache), 2 dropped out at the 2 week interval with no reason 
given, and 1 dropped out due to work related injury. This resulted in 35 patients in the GTN 
group who completed the 6-month trial. The authors reported that 81% (35 of 43) patients in the 
GTN group were asymptomatic with activities of daily living, compared to 60% (26 of 43) in the 
placebo group. A chi-square analysis was done comparing outcomes between the groups that 
showed the GTN group had a significantly increased (p=0.005) chance of being asymptomatic by 
week 24 of the trial. In regards to pain, tenderness, and mean peak force, a Mann-Whitney rank 
sum test was performed, all showing benefit for the GTN patients.2  
 
 
 
 
 
 
Table 2. Paoloni et al. (2003). Effects of Gtn therapy vs placebo on patient rated elbow pain.  
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Pain was decreased most at week 2 of the study (p=0.002), tenderness was measured at 
week 6 and 12, each with improvement and (p=0.02), and peak force at weak 24 was increased 
(p=0.03). According to the journal, “at 6 months, 81% of treated patients were asymptomatic 
during activities of daily living, compared with 60% of patients who had tendon rehabilitation 
alone.” This gives us the Control event rate (CER) of 60%, for the patients with the placebo 
patch, and an Experimental event rate (EER) of 81%. Relative risk reduction (RRR) was 
calculated at 35%, absolute risk reduction at 21%, and numbers needed to treat (NNT) was 5. 
The NNT shows that a practitioner needs to treat 5 patients who have tennis elbow with GTN in 
order to have 1 patient show benefit.2  
The most clinically significant side effects reported were headache in 63% (27/43), and 
dermatitis rash in 21% (9/43).  The placebo group had 58% (25/43) report headache.2  
Paoloni was also involved in an RCT with the British Journal of Sports Medicine. In this 
RCT (Paoloni et al., 2009), used intention to treat analysis of 154 patients, including 18 
discontinued patients (3 dropped from placebo group, 3 from 0.72mg, 4 from 1.44mg, 8 from 
3.6mg). They compared different strengths of GTN, namely OrthoDerm 0.72mg/24h (38 
patients), 1.44mg/24h (30 patients), and 3.6mg/24h (36 patients) with placebo (32 patients). The 
study showed significant improvement in elbow pain with activity at week 8 with the 0.72mg/24 
h verses placebo (P=0.04). The authors discontinued the trial after week 8 due to lack of other 
significant results.  This trial had a CER of 88%, EER of 91%, RRR was 3%, ARR was 3% and 
NNT was 34 in order to improve 1 patient’s symptoms.3  
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The authors mention headache and dermatitis rash as clinically significant side effects for 
treatment with GTN patches, with effects increasing as the dose was increased. Overall, 7 of the 
GTN patients were discontinued due to severe headache (17%).3  
The third study reviewed for this paper was a five-year prospective comparison. There 
were 58 patients who had taken part in the original RCT of 6-month duration: 33 men and 25 
women, with a mean age of 58 (range 40-78).  At 5 years after discontinuation of treatment, the 
results of treatment with GTN verses that with placebo (both with PT) were compared, and found 
to be equally effective. Analysis was performed on patient-rated pain, and there were significant 
improvements in both placebo and GTN groups compared with week 0 of the initial RCT. 
However there was no significant difference in patient pain between the placebo and GTN 
groups for activity pain (p=0.24), rest pain (p=0.16), or night pain (p=0.16) at 5 years. Similarly, 
there was no significant difference in the prevalence of pain with activity (p=0.43) at rest 
(p=0.24) or at night (p=0.26). There were also no significant differences in the prevalence of 
lateral epicondylar tenderness (p=0.52) or in tenderness severity (p=0.16). The P-values here are 
evident of non-significant data between the groups, showing no benefit of using GTN patches as 
therapy.4  
DISCUSSION 
 After review of the results as presented above, it is important to compare and contrast 
efficacy, safety, and real life application of the glyceryl trinitrate for tennis elbow. It does not 
appear that there are many insurance issues, as there were none listed. GTN patches can be 
gotten generically, and use similar compounds found in nitroglycerin used for cardiac ischemia. 
Availability in the U.S. would not be a limitation on treatment with GTN.  
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 It is evident that treatment with topical GTN patches has benefit on pain and tenderness 
for the patient, but only in a short term follow up of six months. The primary study showed that 
there was no significant benefit 5 years from treatment.  
 Limitation of each study- primary (2011)- there was a lack of controlled treatment 
between 6 months and the 5-year study. Also, it is hypothesized that benefit is not seen after 2 
years, so the study may have been done too late. The authors state that a power analysis showed 
they would need 80 patients to have significant data, and although originally recruited, only 58 
were used in the final study. The RCT (2003) mentioned that the physical therapy program was 
not followed closely, as it was done at home. They used verbal patient confirmation that the PT 
was being performed, giving room for possible non-compliance. The RCT (2009) had many 
limitations. The authors stated that after week 8 the study was discontinued due to lack of 
significant results. They stated that there was no exercise program in conjunction with the GTN 
patches, which is a mainstay of treatment, and thus a major weakness of the study. Further 
complicating the study was the use of three different dosages of GTN patches, making sample 
sizes smaller and comparison more difficult.  
 Glyceryl trinitrate is hypothesized to induce nitric oxide release into tendon fibroblasts 
leading to increased collagen synthesis in tendon. However, because of this effect, systemic 
absorption can lead to side effects such as headache, dermatitis rash, and facial flushing. Review 
of drug safety via Lexi-Comp Online mentions careful use of GTN in patients with 
cardiovascular conditions. They remind practitioners to only leave patch in place for 10-12 hours 
and to rotate sites to avoid tolerance.6  
CONCLUSIONS 
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  The three articles reviewed here point to the conclusion that GTN transdermal patches are 
efficacious in treating patient rated pain associated with lateral epicondlyitis. However, only the 
study by Paoloni et al (2003) in the American Journal of Sports Medicine showed concrete 
evidence, as it was the most thourough study. The 2009 Paoloni et al study in the British Journal 
of Sports Medicine was not followed through past 8 weeks, but pointed to positive results with 
GTN therapy if combined with PT concurrently. The prospective study by McCallum et al. 
(2011) showed that there are no long term effects of GTN therapy. They did point out that a 
shorter time may have better results, as a similar study with GTN and Achilles tendonitis had 
efficacy at 3 years.7  
 Looking at these faults, further studies can be proposed to better answer the question of 
GTN efficacy with lateral epicondylitis. Because there was only one RCT that was followed 
through to 6 months, more trials are warranted. Also, rating patient response at 2 years instead of 
at 5 years may prove that there is less pain and tenderness in the GTN group as compared with 
placebo.  
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